抗体药物偶联物靶点在多种肿瘤类型中的全景分析
该研究通过检索PubMed和ClinicalTrials.gov识别了针对59个独特靶点的87种ADC,并利用18 055例患者来源肿瘤样本和3520例健康组织的基因表达谱,预测ADC靶点在60种肿瘤(亚)型中的过表达率。研究发现乳腺癌、结直肠癌、肺腺癌、肺鳞癌和前列腺癌等多种高发肿瘤存在多个ADC靶点的预测过表达率≥10%,罕见肿瘤中 também 观察到高过表达率,如肾上腺皮质癌中CD22和ENPP3均为55%,骨肉瘤中CD74和FGFR3均为81%,葡萄膜黑色素瘤中c-MET为95%。
要点
- 研究识别了87种ADC针对59个独特靶点,覆盖60种肿瘤(亚)型。
- 高发肿瘤中多个ADC靶点预测过表达率≥10%,如乳腺癌31个(三阴性乳腺癌23个)。
- 罕见肿瘤中观察到高过表达率,如葡萄膜黑色素瘤c-MET 95%。
核心结论
- 该研究提供了针对59个独特靶点的临床可用ADC的数据驱动优先级排序,覆盖60种肿瘤(亚)型,可指导临床医生和药物开发者在何种肿瘤(亚)型中进一步评估何种ADC。
研究设计与样本
- 检索PubMed和ClinicalTrials.gov以识别正在或曾在临床试验中评估的ADC。
- 收集公共领域18 055例患者来源肿瘤样本(代表60种肿瘤(亚)型)和3520例健康组织样本的基因表达谱。
- 应用功能基因组mRNA谱分析,以健康组织样本为参考,预测每种肿瘤类型中ADC靶点在蛋白质水平的过表达率。
主要发现
- 识别了87种ADC,针对59个独特靶点。
- 在高发肿瘤类型中观察到多个ADC靶点的预测过表达率≥10%:乳腺癌(n=31,其中三阴性乳腺癌n=23)、结直肠癌(n=18)、肺腺癌(n=18)、肺鳞癌(n=16)、前列腺癌(n=5)。
- 在罕见肿瘤类型中观察到:肾上腺皮质癌中CD22预测过表达率为55%,ENPP3为55%;骨肉瘤中CD74为81%,FGFR3为81%;葡萄膜黑色素瘤中c-MET为95%。
关键数值与推荐
- 预测过表达率≥10%的样本定义为多个ADC靶点的观察阈值。
- 乳腺癌中31个ADC靶点预测过表达率≥10%,其中三阴性乳腺癌中23个。
- 结直肠癌中18个、肺腺癌中18个、肺鳞癌中16个、前列腺癌中5个ADC靶点预测过表达率≥10%。
- 肾上腺皮质癌中CD22和ENPP3预测过表达率均为55%;骨肉瘤中CD74和FGFR3均为81%;葡萄膜黑色素瘤中c-MET为95%。
临床怎么用
- 该ADC靶点全景可指导临床医生和药物开发者判断哪种ADC在哪种肿瘤(亚)型中具有进一步评估的潜在兴趣。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibody-drug conjugates (ADCs), consisting of an antibody designed against a specific target at the cell membrane linked with a cytotoxic agent, are an emerging class of therapeutics. Because ADC tumour cell targets do not have to be drivers of tumour growth, ADCs are potentially relevant for a wide range of tumours currently lacking clear oncogenic drivers. Therefore, we aimed to define the landscape of ADC targets in a broad range of tumours. MATERIALS AND METHODS: PubMed and ClinicalTrials.gov were searched for ADCs that are or were evaluated in clinical trials. Gene expression profiles of 18 055 patient-derived tumour samples representing 60 tumour (sub)types and 3520 healthy tissue samples were collected from the public domain. Next, we applied Functional Genomic mRNA-profiling to predict per tumour type the overexpression rate at the protein level of ADC targets with healthy tissue samples as a reference. RESULTS: We identified 87 ADCs directed against 59 unique targets. A predicted overexpression rate of ≥ 10% of samples for multiple ADC targets was observed for high-incidence tumour types like breast cancer (n = 31 with n = 23 in triple negative breast cancer), colorectal cancer (n = 18), lung adenocarcinoma (n = 18), squamous cell lung cancer (n = 16) and prostate cancer (n = 5). In rare tumour types we observed, amongst others, a predicted overexpression rate of 55% of samples for CD22 and 55% for ENPP3 in adrenocortical carcinomas, 81% for CD74 and 81% for FGFR3 in osteosarcomas, and 95% for c-MET in uveal melanomas. CONCLUSION: This study provides a data-driven prioritization of clinically available ADCs directed against 59 unique targets across 60 tumour (sub)types. This comprehensive ADC target landscape can guide clinicians and drug developers which ADC is of potential interest for further evaluation in which tumour (sub)type.
引用
- Moek KL, de Groot DJA, de Vries EGE, et al. The antibody-drug conjugate target landscape across a broad range of tumour types. Ann Oncol. 2017. PMID: 29045509. doi:10.1093/annonc/mdx541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。